VI Partners

Buynomics GmbH, founded in 2018 and based in Cologne, Germany, specializes in developing and distributing advanced pricing machine software and related solutions. The company leverages artificial intelligence to transform available data into Virtual Customers, which accurately replicate the purchasing behaviors of real consumers. This innovative approach allows organizations in the consumer-packaged goods and telecommunications sectors to gain instant insights into customer preferences without the need for cumbersome analyses or unreliable focus groups. Buynomics’ platform enables Revenue Growth Management teams to optimize essential commercial decisions, including pricing, promotions, and product mix, by providing a comprehensive understanding of critical revenue levers. Through its holistic methodology, Buynomics delivers actionable insights that support profitable and sustainable business strategies.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Kadoa is an AI-powered no-code platform that allows anyone to build complex data workflows effortlessly.

Oplit is a technology company that develops software for optimizing production planning. Its platform uses big data and AI to simulate and compare production strategies, track progress, and facilitate collaboration across departments in real-time.

Somagenetix is a biotechnology company specializing in gene therapy aimed at treating phagocyte-related illnesses. The firm focuses on developing innovative treatments for conditions such as immunodeficiency, neurodegeneration, and cancer with brain metastases. By utilizing genetically modified phagocytes, Somagenetix seeks to improve patient outcomes through targeted therapies. Additionally, the company is engaged in the discovery and development of stem cells derived from bone marrow and therapeutic genes from lentiviral vectors. This approach enables the correction of underlying genetic defects and the transplantation of gene-corrected cells back into patients, with the goal of curing various monogenetic diseases. Through its pioneering efforts, Somagenetix aspires to be a leader in the gene therapy sector.

Almer Technologies specializes in developing compact, lightweight augmented reality (AR) glasses tailored for frontline workers. Their AR as a service includes hardware and software, enabling remote problem-solving and expertise sharing to enhance productivity.

Flowit provides an end-to-end approach that makes modern, digital HR a breeze allowing organizations to streamline their processes.

XO Life operates a digital platform that facilitates patient education, engagement, and monitoring. It offers services such as real-time treatment tracking, patient feedback analysis, and insights exchange between patients and pharmaceutical companies. The platform aims to enhance medication adherence, improve patient outcomes, and foster better communication between patients and healthcare providers.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

LeaseTeq is a FinTech company focused on transforming the automotive leasing experience through innovative digital solutions. Established in 2021, the company provides a digital leasing platform designed to simplify the leasing process for both individuals and businesses. This platform features a fast and convenient application process that is paperless and environmentally friendly, ensuring discretion and security for its users. LeaseTeq aims to enhance user experience by making leasing more accessible and efficient, leveraging technology to address the traditional challenges associated with leasing in the automotive industry.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Acodis specializes in document digitalization software that converts any document into structured data using artificial intelligence. This enables businesses to automate processes, enhance analytics, and integrate data with existing systems.

Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

Ledgy develops a valuation tracking platform to manage equity capital and employee participation. The platform streamlines vesting plans, phantom programs, and numbered shares, digitizing equity management to provide entrepreneurs and shareholders with clear insights into their capital table, financing rounds, and exit talks. Founded in 2017 in Zurich, Switzerland, Ledgy supports startups and growing companies in planning and communicating equity arrangements for stakeholders.

Skribble offers an electronic signature platform that ensures legally binding digital contracts, compliant with Swiss and EU laws. Founded in 2018, it enables users to sign documents electronically with just a few clicks.

Morgen is a software company that specializes in time management solutions. Its flagship product is an integrated platform designed to consolidate various calendars, tasks, projects, and reminders into a single application. This allows users to efficiently plan, organize, and optimize their schedules, reducing the complexity of managing multiple tools. The platform also includes a native scheduling tool for further streamlining meeting arrangements. Morgen caters to both individual users and teams seeking to enhance their time management capabilities.

Ninox is a Berlin-based software company that develops a low-code/no-code platform for building business applications used by teams. The platform enables line-of-business users to automate back-office workflows without developers, blending drag-and-drop design with templates for CRM, invoicing, order management, project planning, to-do lists, time management, and inventory management, as well as data synchronization and mapping. It is designed to digitize and streamline processes across industries while offering easy onboarding and flexible customization. The solution serves more than 2,800 customers, reflecting broad adoption and a focus on improving collaboration and reducing development effort.

Picterra operates an online platform that automates AI object detection workflows to extract geospatial insights from satellite, drone, and aerial imagery. Its cloud-based software enables users to monitor changes, detect patterns, and gain actionable insights across industries such as aerial imaging, finance, insurance, real estate, utilities, and public sector.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Acodis specializes in document digitalization software that converts any document into structured data using artificial intelligence. This enables businesses to automate processes, enhance analytics, and integrate data with existing systems.

Ledgy develops a valuation tracking platform to manage equity capital and employee participation. The platform streamlines vesting plans, phantom programs, and numbered shares, digitizing equity management to provide entrepreneurs and shareholders with clear insights into their capital table, financing rounds, and exit talks. Founded in 2017 in Zurich, Switzerland, Ledgy supports startups and growing companies in planning and communicating equity arrangements for stakeholders.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating mitral valve regurgitation. Founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve designed to be implanted on a beating heart, allowing for the preservation of the native valve structure and surrounding anatomy. HighLife's innovative system facilitates a transseptal delivery through the femoral vein, enabling a reversible approach that minimizes trauma to patients during surgical procedures. The technology is currently undergoing clinical evaluation, with a focus on ensuring ease and safety of use for healthcare providers.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Smart Valor is a Swiss-based blockchain fintech platform that provides a full-stack digital asset service, including a publicly accessible digital asset exchange, custody, and asset management. It offers technology as crypto-as-a-service to banks and fintechs through regulated white-label solutions, enabling financial institutions to access and manage digital assets securely. The platform supports issuance and distribution of tokenized investments across real estate, currencies, venture capital, art, and other assets, and connects KYC, compliance, and performance tools with a decentralized network of investors and service providers. Founded in 2017 and based in Zug, Smart Valor focuses on enabling liquid, regulated, tokenized investing in Europe.

Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Founded in 2002, Athelas develops and manufactures medical devices for remote patient monitoring. Its flagship product is an FDA-cleared blood diagnostic device that enables the detection of infections, inflammations, and malignancies. The company also offers sensors to monitor blood pressure, weight, glucose levels, and medication adherence.

MESA Imaging specializes in the development and production of advanced 3D time-of-flight cameras. The company designs and markets cameras capable of capturing full 3D images at video frame rates, utilizing the Time-of-Flight (TOF) principle. MESA Imaging's technology, including its proprietary silo pixel architecture and the SR4000 sensor chip, enhances distance measurement capabilities, making it suitable for diverse applications across video gaming, machine vision, automotive, and robotics sectors. Through its innovative products, MESA Imaging aims to provide the image-related industries with state-of-the-art camera systems that meet the growing demand for high-quality 3D imaging solutions.

Ledgy develops a valuation tracking platform to manage equity capital and employee participation. The platform streamlines vesting plans, phantom programs, and numbered shares, digitizing equity management to provide entrepreneurs and shareholders with clear insights into their capital table, financing rounds, and exit talks. Founded in 2017 in Zurich, Switzerland, Ledgy supports startups and growing companies in planning and communicating equity arrangements for stakeholders.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

PicoDrill SA is a private company based in Lausanne, Switzerland, specializing in advanced micromachining techniques for creating precise hole structures in various materials, including glass, ceramics, silica, and sapphire. The company has developed a proprietary method known as Electrothermal Focusing, which enables the controlled heating and evaporation of specifically defined volumes in dielectric materials, facilitating the creation of micro-holes and precision cutting. PicoDrill's innovative technologies serve to address the drilling needs within the nanotechnology sector, providing partners and customers with cutting-edge solutions that demonstrate the company's commitment to technology leadership in the industry.

Lambda Health System develops Lambda Robot, a rehabilitation device designed for lower limb therapy. The device enables therapists to perform various exercises without transferring patients between machines. It also offers Lambda Control Center, allowing physicians to monitor patient progress and adapt therapies using games and virtual reality applications.

Advanon AG is a financial services platform based in Zurich, Switzerland, that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015 by Phil Lojacono, Philip Kornmann, and Stijn Pieper, Advanon connects businesses seeking liquidity with a network of financial investors willing to pre-finance their outstanding invoices. This service allows SMEs to access funds more rapidly, avoiding the lengthy wait times of 30 to 120 days typically associated with customer payments. As an authorized financial intermediary, Advanon is regulated under Swiss law, ensuring compliance with the Anti Money Laundering Act. The platform aims to provide flexible financing solutions with transparent pricing, enabling businesses to enhance their cash flow and support growth without incurring additional obligations.

Flytrex is the leading drone-based food delivery service in the United States, specializing in ultrafast deliveries from local restaurants to suburban areas. Operating in North Carolina and Texas, Flytrex has successfully delivered over 120,000 orders for its partners, including Little Caesars, Papa John's, and El Pollo Loco. The company's service is well-received by customers, with a monthly retention rate of 45% after two years, and an NPS score of 75%. Flytrex's drone delivery system significantly reduces delivery costs and times for its partners.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Founded in 2015 as a spin-off of ETH Zurich, Inositec is a biotechnology company that develops novel therapies for soft tissue calcification disorders. It leverages its proprietary Inositune platform to engineer small molecules with tunable properties, focusing on vascular and renal calcification disorders, including orphan indications.

Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Equippo is a commercial equipment company that specializes in buying and selling used construction equipment through its online marketplace. Founded in 2014 and headquartered in Zug, Switzerland, the company connects manufacturers, dealers, leasing companies, and other trusted sellers with buyers worldwide, including regions such as South America, Russia, and Poland. Equippo's platform simplifies the process by offering services such as machine inspection, payment management, shipping, trucking, and customs clearance. A notable feature of its service is the Equippo final price calculation engine, which incorporates tariffs, transport, and logistics specific to the buyer's region, making international transactions more straightforward. With a team that can communicate in over nine languages, Equippo aims to facilitate transparent trading in the heavy equipment sector.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

L.E.S.S. SA is a Swiss company, established in 2012 and headquartered in Renens, that specializes in the design and development of ultra-bright and ultra-thin lighting solutions. The company focuses on creating advanced inspection lighting systems, which encompass microscopy lighting and workbench lighting, as well as automotive lighting. L.E.S.S. offers a range of illumination systems, including high and low angle lighting and shadowless solutions, tailored for diverse applications in automotive, machine vision, watchmaking, micromechanics, electronics, medical fields, and harsh environments. Through its innovative approach, L.E.S.S. aims to deliver lighting solutions that combine intense brightness and uniformity within a compact form factor.

UniKey Technologies specializes in smart access control solutions. It offers a mobile platform that replaces traditional keys with smartphone-based electronic keys, featuring touch-to-open technology, intelligent detection of user location, and robust security measures. The company partners with lock manufacturers like Kwikset and Weiser to create smart locks such as Kevo, and provides cloud-based lock management for multifamily properties and commercial businesses.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sonic Emotion AG is a Swiss company specializing in advanced audio solutions that deliver immersive three-dimensional sound experiences. Founded in 2002 and headquartered in Zurich, the company provides innovative audio technology for a diverse range of applications, including 3D cinemas, events, museums, theme parks, and art installations. Sonic Emotion's proprietary Absolute 3D sound technology enables natural sound reproduction and sound field control, allowing for enhanced auditory experiences with minimal hardware requirements. Additionally, the company offers audio simulation and OEM licensing solutions, as well as the Headquake application, which enhances sound for Apple devices. With research capabilities in France and sales offices across Asia, Sonic Emotion is positioned to meet the growing demand for high-quality audio in various entertainment and commercial sectors.

Edimer Pharmaceuticals is a biotechnology company focused on developing innovative treatments for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as the absence of sweat glands, impaired temperature regulation, respiratory issues, and malformations of hair and teeth. The company's lead product candidate, EDI200, aims to provide significant and lasting improvements in health and quality of life for individuals affected by this condition. Edimer is guided by a team of experienced professionals in the biotechnology sector, supported by a network of distinguished clinical and scientific advisors, all committed to addressing the needs of families impacted by XLHED.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Windeln.de operates as an online retailer specializing in baby, toddler, and children's products across Germany, Austria, Switzerland, the Czech Republic, Spain, and China. It offers a wide range of items including diapers, baby food, clothing, toys, furniture, and safety products like car seats.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Nexthink is a provider of digital employee experience management software that focuses on end-user experience from the endpoint. Its platform delivers real-time analytics and combines endpoint data with end-user feedback to generate actionable intelligence for improving productivity and IT performance. The solution supports incident, problem and change management and offers integration options, including a Digital Experience Score that measures and improves the digital workplace experience by blending hard data with user feedback. Nexthink serves large enterprises across industries worldwide and was founded in 2004, with headquarters in Prilly, Switzerland, and global operations in multiple regions. The technology transforms end-user data into real-time analytics and intelligence across all users, applications and network connections, enabling detection, diagnosis and remediation of issues through machine learning to accelerate troubleshooting, reduce costs and enhance employee experience.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

SilentSoft is a pioneering company in the Machine to Machine (M2M) sector, established in 2000. It specializes in developing a wide range of technologies and processes for the efficient operation of M2M networks. SilentSoft partners with industrial clients to facilitate the deployment and daily management of these networks. The company focuses on telemetry solutions, providing monitoring devices for tanks and meters. By connecting various objects, SilentSoft enables real-time communication and data exchange, helping clients optimize their operations, reduce emergency deliveries, lower fuel consumption, and decrease carbon dioxide emissions.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Edimer Pharmaceuticals is a biotechnology company focused on developing innovative treatments for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as the absence of sweat glands, impaired temperature regulation, respiratory issues, and malformations of hair and teeth. The company's lead product candidate, EDI200, aims to provide significant and lasting improvements in health and quality of life for individuals affected by this condition. Edimer is guided by a team of experienced professionals in the biotechnology sector, supported by a network of distinguished clinical and scientific advisors, all committed to addressing the needs of families impacted by XLHED.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Nexthink is a provider of digital employee experience management software that focuses on end-user experience from the endpoint. Its platform delivers real-time analytics and combines endpoint data with end-user feedback to generate actionable intelligence for improving productivity and IT performance. The solution supports incident, problem and change management and offers integration options, including a Digital Experience Score that measures and improves the digital workplace experience by blending hard data with user feedback. Nexthink serves large enterprises across industries worldwide and was founded in 2004, with headquarters in Prilly, Switzerland, and global operations in multiple regions. The technology transforms end-user data into real-time analytics and intelligence across all users, applications and network connections, enabling detection, diagnosis and remediation of issues through machine learning to accelerate troubleshooting, reduce costs and enhance employee experience.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

Mobileye specializes in developing and deploying advanced driver-assistance systems (ADAS) and autonomous driving technologies. The company leverages expertise in computer vision, machine learning, mapping, and data analysis to optimize mobility infrastructure.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

Nexthink is a provider of digital employee experience management software that focuses on end-user experience from the endpoint. Its platform delivers real-time analytics and combines endpoint data with end-user feedback to generate actionable intelligence for improving productivity and IT performance. The solution supports incident, problem and change management and offers integration options, including a Digital Experience Score that measures and improves the digital workplace experience by blending hard data with user feedback. Nexthink serves large enterprises across industries worldwide and was founded in 2004, with headquarters in Prilly, Switzerland, and global operations in multiple regions. The technology transforms end-user data into real-time analytics and intelligence across all users, applications and network connections, enabling detection, diagnosis and remediation of issues through machine learning to accelerate troubleshooting, reduce costs and enhance employee experience.

Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.